ArticleJOP : Journal of the pancreas2009
Phenotypic CYP2A6 variation and the risk of pancreatic cancer.
Article in JOP : Journal of the pancreas, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group).Investigational new drugs · 2012Trial
- Interaction between heavy smoking and CYP2A6 genotypes on type 2 diabetes and its possible pathways.European journal of endocrinology · 2011Trial
- Article
- Membrane Lipid Derivatives: Roles of Arachidonic Acid and Its Metabolites in Pancreatic Physiology and Pathophysiology.Molecules (Basel, Switzerland) · 2023Review
- Susceptibility loci for pancreatic cancer in the Brazilian population.BMC medical genomics · 2021Article
- Expression of cytochrome P450 isozyme transcripts and activities in human livers.Xenobiotica; the fate of foreign compounds in biological systems · 2021Article
- Genetic polymorphisms of the drug-metabolizing enzyme cytochrome P450 2A6 in a Tibetan Chinese population.International journal of clinical and experimental pathology · 2018Article
- Variation in CYP2A6 Activity and Personalized Medicine.Journal of personalized medicine · 2017Review
- High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population.Omics : a journal of integrative biology · 2014Article
- Enhanced nicotine metabolism in HIV-1-positive smokers compared with HIV-negative smokers: simultaneous determination of nicotine and its four metabolites in their plasma using a simple and sensitive electrospray ionization liquid chromatography-tandem mass spectrometry technique.Drug metabolism and disposition: the biological fate of chemicals · 2014Article
- Article
- Association between daily cigarette consumption and hypertension moderated by CYP2A6 genotypes in Chinese male current smokers.Journal of human hypertension · 2013Article
- PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.Pharmacogenetics and genomics · 2012Review
- An LC-MS/MS method for concurrent determination of nicotine metabolites and the role of CYP2A6 in nicotine metabolite-mediated oxidative stress in SVGA astrocytes.Drug and alcohol dependence · 2012Article
- Relationship between amounts of daily cigarette consumption and abdominal obesity moderated by CYP2A6 genotypes in Chinese male current smokers.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2012Article
- A LC-MS/MS method for concurrent determination of nicotine metabolites and role of CYP2A6 in nicotine metabolism in U937 macrophages: implications in oxidative stress in HIV + smokers.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2012Article
- Sex Differences in the Expression of Drug-Metabolizing and Transporter Genes in Human Liver.Journal of drug metabolism & toxicology · 2012Article
- The role of tobacco-derived carcinogens in pancreas cancer.ISRN oncology · 2011Article
- Current status of molecular markers for early detection of sporadic pancreatic cancer.Biochimica et biophysica acta · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveCytochrome P450 2A6 (CYP2A6) is an important metabolic enzyme capable of activating several procarcinogens, including dietary and tobacco-specific nitrosamines, which have been linked to pancreatic cancer. Positive associations between high CYP2A6 activity and lung and colorectal cancers have been reported. This is the first investigation of CYP2A6 activity and pancreatic cancer.
designIn this case-control study of cancer of the exocrine pancreas, phenotypic CYP2A6 activity was measured using a ratio of urinary caffeine metabolites. Demographic, smoking, dietary and medical information were obtained by questionnaire. CYP2A6 phenotype, which is not influenced by smoking status, was measured for 90 cases and 470 controls.
resultsWhen modeled as a continuous variable, and adjusted for age, sex, race, education, current smoking status and chronic pancreatitis, the odds ratio (OR) per one unit of the natural log of the CYP2A6 ratio was 1.52 (95% confidence interval, CI: 1.09-2.12). In an adjusted categorical analysis, subjects in the uppermost quartile (based on controls) of CYP2A6 activity, when compared to the lower three quartiles, carried an 80% greater risk of pancreatic cancer (OR=1.80; 95% CI: 1.07-3.02).
conclusionsHigh levels of CYP2A6 activity, as measured by a caffeine phenotyping assay, were positively associated with pancreatic cancer in this casecontrol study among a Midwestern U.S. population.
Indexed as
Identifiers
19454817PMC4397970W2125880466What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.